[1] Basu R, Noureddin M, Clark JM. Nonalcoholic fatty liver disease: review of management for primary care providers[J]. Mayo Clin Proc, 2022, 97(9):1700-1716. [2] Vachliotis ID, Anastasilakis AD, Goulas A, et al. Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications[J]. Diabetes Obes Metab, 2022, 24(9):1702-1720. [3] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies[J]. Gut, 2022, 71(4):778-788. [4] Nassir F. NAFLD: mechanisms, treatments, and biomarkers[J]. Biomolecules, 2022, 12(6):824. [5] Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis[J]. J Hepatol, 2021, 75(4):770-785. [6] Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review[J]. Liver Int, 2021, 41(2):261-270. [7] Amernia B, Moosavy SH, Banookh F, et al. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran[J]. BMC Gastroenterol, 2021, 21(1):453-459. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志, 2018, 26(3):195-203. [9] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南(2019年版)[J].中华肝脏病杂志, 2019, 27(7):494-504. [10] 张洪, 张佳, 周家龙, 等. 肝静脉直径、改良肝尾叶/右叶比值对肝纤维化和肝硬化病理学分期的诊断价值[J]. 中国医学影像学杂志, 2020, 28(7):529-532+534. [11] Raza S, Rajak S, Upadhyay A, et al. Current treatment paradigms and emerging therapies for NAFLD/NASH[J]. Front Biosci (Landmark Ed), 2021, 26(2):206-237. [12] 胡漂, 孔东明, 朱仲鑫. 1990—2019年中国人群非酒精性脂肪肝疾病负担分析[J]. 中国预防医学杂志, 2022, 23(4):260-264. [13] Li L, Huang Q, Yang L, et al. The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with serological vitamin B12 markers: results from the NHANES 1999-2004[J]. Nutrients, 2022, 14(6):1224-1238. [14] Brandman D, Boyle M, McPherson S, et al. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)[J]. Aliment Pharmacol Ther, 2022, 55(11):1441-1451. [15] Liguori A, Zoncapè M, Tsochatzis EA. Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease[J]. Rev Esp Enferm Dig, 2022, 114(4):191-194. [16] Nielsen MJ, Leeming DJ, Goodman Z, et al. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population[J]. J Hepatol, 2021, 75(6):1292-1300. [17] Ozturk A, Olson MC, Samir AE, et al. Liver fibrosis assessment: MR and US elastography[J]. Abdom Radiol (NY), 2022, 47(9):3037-3050. [18] Zhao Y, Li H. Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease[J]. Scand J Gastroenterol, 2022, 57(7):872-877. [19] 金舟, 谭承富, 丁华. 改良肝尾叶与右叶比值在肝炎后肝硬化CT诊断中的价值[J]. 西部医学, 2018, 30(3):442-445. [20] Suarez-Quintero CY, Patarroyo Henao O, Mu?oz-Velandia O. Concordance between hepatic biopsy and the APRI index for the diagnosis of cirrhosis in patients with autoimmune liver disease[J]. Gastroenterol Hepatol, 2021, 44(7):465-471. [21] Han S, Choi M, Lee B, et al. Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Gut Liver, 2022, 16(6):952-963. [22] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中国肝脏病杂, 2019, 11(4):5-27. [23] 马晓辉, 张新, 游云, 等. APRI、FIB-4联合对慢性乙型肝炎患者显著肝纤维化的诊断价值[J]. 胃肠病学, 2017, 22(9):544-547. [24] 唐龙, 邓永琼, 王鸿, 等. 无创肝纤维化模型对慢性乙型病毒性肝炎肝纤维化的诊断价值研究[J].中国全科医学, 2020, 23(27):3408-3415. |